Abstract
PURPOSE OF REVIEW: The successful introduction of the tyrosine kinase inhibitors has initiated a new era in the management of chronic myeloid leukemia. RECENT FINDINGS: Imatinib therapy has significantly improved prognosis of chronic myeloid leukemia. A minority of patients with chronic-phase disease (4% annually) and considerably more in advanced stages develop resistance. This is attributed, in 40-50% of cases, to the development of BCR-ABL (breakpoint cluster region/Abelson oncogene) tyrosine kinase domain mutations that impair imatinib binding. This has led to the development of more potent novel tyrosine kinase inhibitors that can overcome both BCR-ABL-dependent and BCR-ABL-independent mechanisms of resistance. Preliminary results of phase I and II trials with dasatinib and nilotinib have provided promising data that may reduce disease progression and potentially prevent acquired resistance to the tyrosine kinase inhibitors. SUMMARY: Novel tyrosine kinase inhibitors with more potent and selective Bcr-Abl inhibition and with multitargeted inhibition of Bcr-Abl and Src family kinases are promising and may further improve prognosis in chronic myeloid leukemia.
Original language | English (US) |
---|---|
Pages (from-to) | 578-583 |
Number of pages | 6 |
Journal | Current opinion in oncology |
Volume | 18 |
Issue number | 6 |
DOIs | |
State | Published - Nov 2006 |
Keywords
- Chronic myeloid leukemia
- Imatinib
- Mutations
- Novel tyrosine kinase inhibitors
- Resistance
ASJC Scopus subject areas
- Oncology
- Cancer Research